|Mind Medicine Australia has submitted Australia’s first applications to Australia’s Therapeutic Goods Administration (TGA) tor the rescheduling of psilocybin and MDMA for medicinal use from Schedule 9 (Prohibited Substances) to Schedule 8 (Controlled Medicines).
This will enable psychiatrists and specialist addiction physicians to more easily access these medicines to augment therapy for patients suffering from key mental illnesses such as depression, PTSD and for the depression and anxiety often associated with a terminal illness diagnosis (and hopefully in the future for substance abuse, OCD, anorexia and early stage dementia). It will also relieve a significant part of the regulatory burden associated with undertaking trials with these medicines in Australia. The changes proposed by Mind Medicine Australia will not affect existing legal controls on illicit use or supply.
With only a short time left, we are inviting you to support our applications for the rescheduling of these two medicines by lodging your ownsupporting submissions with the TGA no later than Monday 28 September 2021. The rescheduling of these medicines would be a historic moment for all of us!